When you live with a chronic disease like lupus, it's often hard to answer "How ya doin'?" the first time, writes columnist ...

Lupus News Today is a digital platform intended to provide the lupus community with the most recent news and information, as well as first-hand community perspectives from our patient and caregiver ...

Few couples hearing the term “in sickness and in health” at their wedding have thoughts of chronic illness enter their mind. But the reality is, with almost half of the American population dealing ...

During a random conversation, a family member, one of the smartest little humans in my life, told me about the books she’s been reading. One is nonfiction and the other is young adult fantasy. She was ...

An associate professor of biomedical engineering at the University of Houston is developing a new way to deliver treatments for lupus directly to the spleen, which is the home of certain immune cells ...

The Lupus Research Alliance (LRA) and its clinical research affiliate, Lupus Therapeutics, have launched the largest, long-term prospective observational study in lupus with the goal of developing new ...

Telitacicept, a B-cell-targeting therapy developed by RemeGen, outperformed a placebo at reducing the severity of systemic lupus erythematosus (SLE) in a Phase 3 clinical trial in China, the company ...

Lupuzor (rigerimod, or IPP-201101) combined with standard therapy did not demonstrate a statistically significant response rate in systemic lupus erythematosus (SLE) patients over standard care alone, ...

When you live with a chronic illness like lupus, you eventually learn that energy isn’t just something you “have” or “don’t have.” It’s sacred. It’s currency. And when it’s gone, it’s gone. Unlike a ...

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has awarded $3 million to a research team that’s using artificial intelligence (AI) to diagnose lupus nephritis, one of the ...

Brepocitinib, an investigational oral therapy, failed to show any benefits beyond a placebo in a Phase 2 clinical trial that tested it in adults with moderate to severely active systemic lupus ...

The U.S. Food and Drug Administration (FDA) has agreed to allow Kyverna Therapeutics to begin clinical testing of KYV-101, the company’s investigational cell therapy for lupus nephritis, a form of ...